Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine.

Perez JL, Absalon J, Beeslaar J, Balmer P, Jansen KU, Jones TR, Harris S, York LJ, Jiang Q, Radley D, Anderson AS, Crowther G, Eiden JJ.

Expert Rev Vaccines. 2018 Jun;17(6):461-477. doi: 10.1080/14760584.2018.1483726. Epub 2018 Jun 22. Review.

PMID:
29883226
2.

Fragment-Based Screening of a Natural Product Library against 62 Potential Malaria Drug Targets Employing Native Mass Spectrometry.

Vu H, Pedro L, Mak T, McCormick B, Rowley J, Liu M, Di Capua A, Williams-Noonan B, Pham NB, Pouwer R, Nguyen B, Andrews KT, Skinner-Adams T, Kim J, Hol WGJ, Hui R, Crowther GJ, Van Voorhis WC, Quinn RJ.

ACS Infect Dis. 2018 Apr 13;4(4):431-444. doi: 10.1021/acsinfecdis.7b00197. Epub 2018 Mar 3.

3.

The barriers and facilitators for recognising distress in people with severe dementia on general hospital wards.

Crowther GJE, Brennan CA, Bennett MI.

Age Ageing. 2018 May 1;47(3):458-465. doi: 10.1093/ageing/afx198.

4.

Which way do the ions go? A graph-drawing exercise for understanding electrochemical gradients.

Crowther GJ.

Adv Physiol Educ. 2017 Dec 1;41(4):556-559. doi: 10.1152/advan.00111.2017. No abstract available.

5.

Docbate: A National Medical Student Debate.

Keynejad RC, Creed S, Fernando M, Bell D, Codling D, Crowther G, Harrison JR, Jaleel S, Kendall K, Megahey L, Noble E, O'Donnell C, Pilcher F, Walker T, McLaughlan D.

Acad Psychiatry. 2017 Dec;41(6):839-841. doi: 10.1007/s40596-017-0697-1. Epub 2017 Mar 17. No abstract available.

6.

How well are the diagnosis and symptoms of dementia recorded in older patients admitted to hospital?

Crowther GJ, Bennett MI, Holmes JD.

Age Ageing. 2017 Jan 10;46(1):112-118. doi: 10.1093/ageing/afw169.

PMID:
28181654
7.

Association of Fidaxomicin with C. difficile Spores: Effects of Persistence on Subsequent Spore Recovery, Outgrowth and Toxin Production.

Chilton CH, Crowther GS, Ashwin H, Longshaw CM, Wilcox MH.

PLoS One. 2016 Aug 24;11(8):e0161200. doi: 10.1371/journal.pone.0161200. eCollection 2016.

8.

An In Vitro Model of the Human Colon: Studies of Intestinal Biofilms and Clostridium difficile Infection.

Crowther GS, Wilcox MH, Chilton CH.

Methods Mol Biol. 2016;1476:223-34. doi: 10.1007/978-1-4939-6361-4_17.

9.

Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond.

Van Voorhis WC, Adams JH, Adelfio R, Ahyong V, Akabas MH, Alano P, Alday A, Alemán Resto Y, Alsibaee A, Alzualde A, Andrews KT, Avery SV, Avery VM, Ayong L, Baker M, Baker S, Ben Mamoun C, Bhatia S, Bickle Q, Bounaadja L, Bowling T, Bosch J, Boucher LE, Boyom FF, Brea J, Brennan M, Burton A, Caffrey CR, Camarda G, Carrasquilla M, Carter D, Belen Cassera M, Chih-Chien Cheng K, Chindaudomsate W, Chubb A, Colon BL, Colón-López DD, Corbett Y, Crowther GJ, Cowan N, D'Alessandro S, Le Dang N, Delves M, DeRisi JL, Du AY, Duffy S, Abd El-Salam El-Sayed S, Ferdig MT, Fernández Robledo JA, Fidock DA, Florent I, Fokou PV, Galstian A, Gamo FJ, Gokool S, Gold B, Golub T, Goldgof GM, Guha R, Guiguemde WA, Gural N, Guy RK, Hansen MA, Hanson KK, Hemphill A, Hooft van Huijsduijnen R, Horii T, Horrocks P, Hughes TB, Huston C, Igarashi I, Ingram-Sieber K, Itoe MA, Jadhav A, Naranuntarat Jensen A, Jensen LT, Jiang RH, Kaiser A, Keiser J, Ketas T, Kicka S, Kim S, Kirk K, Kumar VP, Kyle DE, Lafuente MJ, Landfear S, Lee N, Lee S, Lehane AM, Li F, Little D, Liu L, Llinás M, Loza MI, Lubar A, Lucantoni L, Lucet I, Maes L, Mancama D, Mansour NR, March S, McGowan S, Medina Vera I, Meister S, Mercer L, Mestres J, Mfopa AN, Misra RN, Moon S, Moore JP, Morais Rodrigues da Costa F, Müller J, Muriana A, Nakazawa Hewitt S, Nare B, Nathan C, Narraidoo N, Nawaratna S, Ojo KK, Ortiz D, Panic G, Papadatos G, Parapini S, Patra K, Pham N, Prats S, Plouffe DM, Poulsen SA, Pradhan A, Quevedo C, Quinn RJ, Rice CA, Abdo Rizk M, Ruecker A, St Onge R, Salgado Ferreira R, Samra J, Robinett NG, Schlecht U, Schmitt M, Silva Villela F, Silvestrini F, Sinden R, Smith DA, Soldati T, Spitzmüller A, Stamm SM, Sullivan DJ, Sullivan W, Suresh S, Suzuki BM, Suzuki Y, Swamidass SJ, Taramelli D, Tchokouaha LR, Theron A, Thomas D, Tonissen KF, Townson S, Tripathi AK, Trofimov V, Udenze KO, Ullah I, Vallieres C, Vigil E, Vinetz JM, Voong Vinh P, Vu H, Watanabe NA, Weatherby K, White PM, Wilks AF, Winzeler EA, Wojcik E, Wree M, Wu W, Yokoyama N, Zollo PH, Abla N, Blasco B, Burrows J, Laleu B, Leroy D, Spangenberg T, Wells T, Willis PA.

PLoS Pathog. 2016 Jul 28;12(7):e1005763. doi: 10.1371/journal.ppat.1005763. eCollection 2016 Jul.

10.

Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.

Crowther GJ, Hillesland HK, Keyloun KR, Reid MC, Lafuente-Monasterio MJ, Ghidelli-Disse S, Leonard SE, He P, Jones JC, Krahn MM, Mo JS, Dasari KS, Fox AM, Boesche M, El Bakkouri M, Rivas KL, Leroy D, Hui R, Drewes G, Maly DJ, Van Voorhis WC, Ojo KK.

PLoS One. 2016 Mar 2;11(3):e0149996. doi: 10.1371/journal.pone.0149996. eCollection 2016.

11.

Bioaffinity Mass Spectrometry Screening.

Yang B, Feng YJ, Vu H, McCormick B, Rowley J, Pedro L, Crowther GJ, Van Voorhis WC, Forster PI, Quinn RJ.

J Biomol Screen. 2016 Feb;21(2):194-200. doi: 10.1177/1087057115622605.

PMID:
26773071
12.

Potential of lactoferrin to prevent antibiotic-induced Clostridium difficile infection.

Chilton CH, Crowther GS, Śpiewak K, Brindell M, Singh G, Wilcox MH, Monaghan TM.

J Antimicrob Chemother. 2016 Apr;71(4):975-85. doi: 10.1093/jac/dkv452. Epub 2016 Jan 11.

13.

Efficacy of vancomycin extended-dosing regimens for treatment of simulated Clostridium difficile infection within an in vitro human gut model.

Crowther GS, Chilton CH, Longshaw C, Todhunter SL, Ewin D, Vernon J, Karas A, Wilcox MH.

J Antimicrob Chemother. 2016 Apr;71(4):986-91. doi: 10.1093/jac/dkv453. Epub 2016 Jan 10.

14.

Meningococcal Serogroup B Bivalent rLP2086 Vaccine Elicits Broad and Robust Serum Bactericidal Responses in Healthy Adolescents.

Vesikari T, Østergaard L, Diez-Domingo J, Wysocki J, Flodmark CE, Beeslaar J, Eiden J, Jiang Q, Jansen KU, Jones TR, Harris SL, O'Neill RE, York LJ, Crowther G, Perez JL.

J Pediatric Infect Dis Soc. 2016 Jun;5(2):152-60. doi: 10.1093/jpids/piv039. Epub 2015 Aug 4.

15.

Antibiotic therapy and Clostridium difficile infection - primum non nocere - first do no harm.

Crowther GS, Wilcox MH.

Infect Drug Resist. 2015 Sep 15;8:333-7. doi: 10.2147/IDR.S87224. eCollection 2015.

16.

High-throughput screening against thioredoxin glutathione reductase identifies novel inhibitors with potential therapeutic value for schistosomiasis.

Li T, Ziniel PD, He PQ, Kommer VP, Crowther GJ, He M, Liu Q, Van Voorhis WC, Williams DL, Wang MW.

Infect Dis Poverty. 2015 Aug 31;4:40. doi: 10.1186/s40249-015-0071-z.

17.

Efficacy of alternative fidaxomicin dosing regimens for treatment of simulated Clostridium difficile infection in an in vitro human gut model.

Chilton CH, Crowther GS, Todhunter SL, Ashwin H, Longshaw CM, Karas A, Wilcox MH.

J Antimicrob Chemother. 2015 Sep;70(9):2598-607. doi: 10.1093/jac/dkv156. Epub 2015 Jun 14.

18.

The Bacterial Sec Pathway of Protein Export: Screening and Follow-Up.

Crowther GJ, Weller SM, Jones JC, Weaver T, Fan E, Van Voorhis WC, Rosen H.

J Biomol Screen. 2015 Aug;20(7):921-6. doi: 10.1177/1087057115587458. Epub 2015 May 18.

PMID:
25987586
19.

Recurrence of dual-strain Clostridium difficile infection in an in vitro human gut model.

Crowther GS, Chilton CH, Todhunter SL, Nicholson S, Freeman J, Wilcox MH.

J Antimicrob Chemother. 2015 Aug;70(8):2316-21. doi: 10.1093/jac/dkv108. Epub 2015 Apr 29.

20.

Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.

Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, van Werkhoven CH, van Deursen AM, Sanders EA, Verheij TJ, Patton M, McDonough A, Moradoghli-Haftvani A, Smith H, Mellelieu T, Pride MW, Crowther G, Schmoele-Thoma B, Scott DA, Jansen KU, Lobatto R, Oosterman B, Visser N, Caspers E, Smorenburg A, Emini EA, Gruber WC, Grobbee DE.

N Engl J Med. 2015 Mar 19;372(12):1114-25. doi: 10.1056/NEJMoa1408544.

21.

In vitro susceptibility of Clostridium difficile to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against C. difficile.

Corbett D, Wise A, Birchall S, Warn P, Baines SD, Crowther G, Freeman J, Chilton CH, Vernon J, Wilcox MH, Vickers RJ.

J Antimicrob Chemother. 2015;70(6):1751-6. doi: 10.1093/jac/dkv006. Epub 2015 Feb 3.

22.

SMT19969 as a treatment for Clostridium difficile infection: an assessment of antimicrobial activity using conventional susceptibility testing and an in vitro gut model.

Baines SD, Crowther GS, Freeman J, Todhunter S, Vickers R, Wilcox MH.

J Antimicrob Chemother. 2015 Jan;70(1):182-9. doi: 10.1093/jac/dku324. Epub 2014 Sep 3.

23.

Efficacy of surotomycin in an in vitro gut model of Clostridium difficile infection.

Chilton CH, Crowther GS, Todhunter SL, Nicholson S, Freeman J, Chesnel L, Wilcox MH.

J Antimicrob Chemother. 2014 Sep;69(9):2426-33. doi: 10.1093/jac/dku141. Epub 2014 May 9.

PMID:
24816211
24.

Comparison of planktonic and biofilm-associated communities of Clostridium difficile and indigenous gut microbiota in a triple-stage chemostat gut model.

Crowther GS, Chilton CH, Todhunter SL, Nicholson S, Freeman J, Baines SD, Wilcox MH.

J Antimicrob Chemother. 2014 Aug;69(8):2137-47. doi: 10.1093/jac/dku116. Epub 2014 Apr 30.

PMID:
24788662
25.

Re: misconceptions are "so yesterday!".

Crowther GJ, Price RM.

CBE Life Sci Educ. 2014 Spring;13(1):3-5. doi: 10.1187/cbe.13-11-0226. No abstract available.

26.

Development and validation of a chemostat gut model to study both planktonic and biofilm modes of growth of Clostridium difficile and human microbiota.

Crowther GS, Chilton CH, Todhunter SL, Nicholson S, Freeman J, Baines SD, Wilcox MH.

PLoS One. 2014 Feb 6;9(2):e88396. doi: 10.1371/journal.pone.0088396. eCollection 2014.

27.

Cofactor-independent phosphoglycerate mutase from nematodes has limited druggability, as revealed by two high-throughput screens.

Crowther GJ, Booker ML, He M, Li T, Raverdy S, Novelli JF, He P, Dale NR, Fife AM, Barker RH Jr, Kramer ML, Van Voorhis WC, Carlow CK, Wang MW.

PLoS Negl Trop Dis. 2014 Jan 9;8(1):e2628. doi: 10.1371/journal.pntd.0002628. eCollection 2014.

28.

In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection.

Chilton CH, Crowther GS, Baines SD, Todhunter SL, Freeman J, Locher HH, Athanasiou A, Wilcox MH.

J Antimicrob Chemother. 2014 Mar;69(3):697-705. doi: 10.1093/jac/dkt411. Epub 2013 Oct 14.

PMID:
24128668
29.

Plasmodium gametocyte inhibition identified from a natural-product-based fragment library.

Vu H, Roullier C, Campitelli M, Trenholme KR, Gardiner DL, Andrews KT, Skinner-Adams T, Crowther GJ, Van Voorhis WC, Quinn RJ.

ACS Chem Biol. 2013 Dec 20;8(12):2654-9. doi: 10.1021/cb400582b. Epub 2013 Oct 3.

PMID:
24079418
30.

Successful treatment of simulated Clostridium difficile infection in a human gut model by fidaxomicin first line and after vancomycin or metronidazole failure.

Chilton CH, Crowther GS, Freeman J, Todhunter SL, Nicholson S, Longshaw CM, Wilcox MH.

J Antimicrob Chemother. 2014 Feb;69(2):451-62. doi: 10.1093/jac/dkt347. Epub 2013 Sep 3.

PMID:
24003182
31.

Evaluation of the effect of oritavancin on Clostridium difficile spore germination, outgrowth and recovery.

Chilton CH, Freeman J, Baines SD, Crowther GS, Nicholson S, Wilcox MH.

J Antimicrob Chemother. 2013 Sep;68(9):2078-82. doi: 10.1093/jac/dkt160. Epub 2013 Jun 11.

PMID:
23759507
32.

Evaluation of antimicrobial activity of ceftaroline against Clostridium difficile and propensity to induce C. difficile infection in an in vitro human gut model.

Baines SD, Chilton CH, Crowther GS, Todhunter SL, Freeman J, Wilcox MH.

J Antimicrob Chemother. 2013 Aug;68(8):1842-9. doi: 10.1093/jac/dkt107. Epub 2013 Apr 3.

PMID:
23557928
33.

Mixed infection by Clostridium difficile in an in vitro model of the human gut.

Baines SD, Crowther GS, Todhunter SL, Freeman J, Chilton CH, Fawley WN, Wilcox MH.

J Antimicrob Chemother. 2013 May;68(5):1139-43. doi: 10.1093/jac/dks529. Epub 2013 Jan 25.

PMID:
23354280
34.

Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection.

Crowther GS, Baines SD, Todhunter SL, Freeman J, Chilton CH, Wilcox MH.

J Antimicrob Chemother. 2013 Jan;68(1):168-76. doi: 10.1093/jac/dks359. Epub 2012 Sep 10.

PMID:
22966180
35.

Oritavancin does not induce Clostridium difficile germination and toxin production in hamsters or a human gut model.

Freeman J, Marquis M, Crowther GS, Todhunter SL, Fawley WN, Chilton CH, Moeck G, Lehoux D, Wilcox MH.

J Antimicrob Chemother. 2012 Dec;67(12):2919-26. doi: 10.1093/jac/dks309. Epub 2012 Aug 16.

PMID:
22899803
36.

Effectiveness of a short (4 day) course of oritavancin in the treatment of simulated Clostridium difficile infection using a human gut model.

Chilton CH, Freeman J, Crowther GS, Todhunter SL, Wilcox MH.

J Antimicrob Chemother. 2012 Oct;67(10):2434-7. doi: 10.1093/jac/dks243. Epub 2012 Jun 21.

PMID:
22723601
37.

Using science songs to enhance learning: an interdisciplinary approach.

Crowther G.

CBE Life Sci Educ. 2012 Spring;11(1):26-30. doi: 10.1187/cbe.11-08-0068. Review.

38.

Co-amoxiclav induces proliferation and cytotoxin production of Clostridium difficile ribotype 027 in a human gut model.

Chilton CH, Freeman J, Crowther GS, Todhunter SL, Nicholson S, Wilcox MH.

J Antimicrob Chemother. 2012 Apr;67(4):951-4. doi: 10.1093/jac/dkr584. Epub 2012 Jan 25.

PMID:
22279183
39.

A mechanism-based whole-cell screening assay to identify inhibitors of protein export in Escherichia coli by the Sec pathway.

Crowther GJ, Quadri SA, Shannon-Alferes BJ, Van Voorhis WC, Rosen H.

J Biomol Screen. 2012 Apr;17(4):535-41. doi: 10.1177/1087057111431606. Epub 2012 Jan 10.

PMID:
22233648
40.

TDR Targets: a chemogenomics resource for neglected diseases.

Magariños MP, Carmona SJ, Crowther GJ, Ralph SA, Roos DS, Shanmugam D, Van Voorhis WC, Agüero F.

Nucleic Acids Res. 2012 Jan;40(Database issue):D1118-27. doi: 10.1093/nar/gkr1053. Epub 2011 Nov 23.

41.

Expression of proteins in Escherichia coli as fusions with maltose-binding protein to rescue non-expressed targets in a high-throughput protein-expression and purification pipeline.

Hewitt SN, Choi R, Kelley A, Crowther GJ, Napuli AJ, Van Voorhis WC.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2011 Sep 1;67(Pt 9):1006-9. doi: 10.1107/S1744309111022159. Epub 2011 Aug 13.

42.

A systems biology approach uncovers cellular strategies used by Methylobacterium extorquens AM1 during the switch from multi- to single-carbon growth.

Skovran E, Crowther GJ, Guo X, Yang S, Lidstrom ME.

PLoS One. 2010 Nov 24;5(11):e14091. doi: 10.1371/journal.pone.0014091.

43.

Identification of inhibitors for putative malaria drug targets among novel antimalarial compounds.

Crowther GJ, Napuli AJ, Gilligan JH, Gagaring K, Borboa R, Francek C, Chen Z, Dagostino EF, Stockmyer JB, Wang Y, Rodenbough PP, Castaneda LJ, Leibly DJ, Bhandari J, Gelb MH, Brinker A, Engels IH, Taylor J, Chatterjee AK, Fantauzzi P, Glynne RJ, Van Voorhis WC, Kuhen KL.

Mol Biochem Parasitol. 2011 Jan;175(1):21-9. doi: 10.1016/j.molbiopara.2010.08.005. Epub 2010 Sep 15.

44.

Identification of attractive drug targets in neglected-disease pathogens using an in silico approach.

Crowther GJ, Shanmugam D, Carmona SJ, Doyle MA, Hertz-Fowler C, Berriman M, Nwaka S, Ralph SA, Roos DS, Van Voorhis WC, Agüero F.

PLoS Negl Trop Dis. 2010 Aug 24;4(8):e804. doi: 10.1371/journal.pntd.0000804.

45.

Chemical genetics of Plasmodium falciparum.

Guiguemde WA, Shelat AA, Bouck D, Duffy S, Crowther GJ, Davis PH, Smithson DC, Connelly M, Clark J, Zhu F, Jiménez-Díaz MB, Martinez MS, Wilson EB, Tripathi AK, Gut J, Sharlow ER, Bathurst I, El Mazouni F, Fowble JW, Forquer I, McGinley PL, Castro S, Angulo-Barturen I, Ferrer S, Rosenthal PJ, Derisi JL, Sullivan DJ, Lazo JS, Roos DS, Riscoe MK, Phillips MA, Rathod PK, Van Voorhis WC, Avery VM, Guy RK.

Nature. 2010 May 20;465(7296):311-5. doi: 10.1038/nature09099.

46.

Use of thermal melt curves to assess the quality of enzyme preparations.

Crowther GJ, He P, Rodenbough PP, Thomas AP, Kovzun KV, Leibly DJ, Bhandari J, Castaneda LJ, Hol WG, Gelb MH, Napuli AJ, Van Voorhis WC.

Anal Biochem. 2010 Apr 15;399(2):268-75. doi: 10.1016/j.ab.2009.12.018. Epub 2009 Dec 14.

47.

Buffer optimization of thermal melt assays of Plasmodium proteins for detection of small-molecule ligands.

Crowther GJ, Napuli AJ, Thomas AP, Chung DJ, Kovzun KV, Leibly DJ, Castaneda LJ, Bhandari J, Damman CJ, Hui R, Hol WG, Buckner FS, Verlinde CL, Zhang Z, Fan E, van Voorhis WC.

J Biomol Screen. 2009 Jul;14(6):700-7. doi: 10.1177/1087057109335749. Epub 2009 May 21.

48.

Genomic-scale prioritization of drug targets: the TDR Targets database.

Agüero F, Al-Lazikani B, Aslett M, Berriman M, Buckner FS, Campbell RK, Carmona S, Carruthers IM, Chan AW, Chen F, Crowther GJ, Doyle MA, Hertz-Fowler C, Hopkins AL, McAllister G, Nwaka S, Overington JP, Pain A, Paolini GV, Pieper U, Ralph SA, Riechers A, Roos DS, Sali A, Shanmugam D, Suzuki T, Van Voorhis WC, Verlinde CL.

Nat Rev Drug Discov. 2008 Nov;7(11):900-7. doi: 10.1038/nrd2684. Epub 2008 Oct 17. Review.

49.

Formate as the main branch point for methylotrophic metabolism in Methylobacterium extorquens AM1.

Crowther GJ, Kosály G, Lidstrom ME.

J Bacteriol. 2008 Jul;190(14):5057-62. doi: 10.1128/JB.00228-08. Epub 2008 May 23.

50.

Identification of a fourth formate dehydrogenase in Methylobacterium extorquens AM1 and confirmation of the essential role of formate oxidation in methylotrophy.

Chistoserdova L, Crowther GJ, Vorholt JA, Skovran E, Portais JC, Lidstrom ME.

J Bacteriol. 2007 Dec;189(24):9076-81. Epub 2007 Oct 5.

Supplemental Content

Loading ...
Support Center